st April 16, 2024 Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate o ...

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.Johnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street's expectations as sales in its medical devices business surged.Meanwhile, the company's total revenue for the period was largely in line with estimates.J&J's medtech division provides devices for surgeries, orthopedics and vision. The company is benefiting from a rebound in demand for nonurgent surgeries among ol ...

Investors are always looking for stocks that are poised to beat at earnings season and Johnson & Johnson (JNJ) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Johnson & Johnson is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty ...

CHINA - 2023/02/15: In this photo illustration, the American multinational medical devices and ... [+] pharmaceutical company Johnson & Johnson (J&J) logo is seen displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. We expect the company to post revenue of $21.5 bill ...

JHVEPhotoOverview Johnson & Johnson (NYSE:JNJ) has always been one of those companies that has a product and service offering so wide and large that JNJ can be considered its own healthcare ETF. Johnson & Johnson operates within the healthcare space with focus on some of the following segments: immunology, infections, neuroscience, and oncology to name a few. In addition, they also operate a segment called MedTech, that provides interventional solutions. With solid financials, a consistent dividend stre ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2.64 per share in its forthcoming report, representing a decline of 1.5% year over year. Revenues are projected to reach $21.38 billion, declining 13.6% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during th ...

JOHANNESBURG, April 10 (Reuters) - Nigeria's health regulator is recalling a batch of Johnson & Johnson (JNJ.N)New Tab, opens new tab children's cough syrup after finding an unacceptably high level of a potentially fatal toxic substance, it said on Wednesday.Laboratory tests on Benylin Paediatric showed a high level of diethylene glycol, which has been linked to the deaths of dozens of children in Gambia, Uzbekistan and Cameroon since 2022 in one of the world's worst waves of poisoning from oral medication. ...

GERMANY - 2024/02/16: In this photo illustration, a Johnson & Johnson logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson (NYSE: JNJ) recently announced its plans to acquire Shockwave Medical for $13 billion. Shockwave will help J&J extend its offerings in the cardiovascular intervention market. This acquisition will expand sales growth for J&J’s MedTech segment, which has seen its sa ...